GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phathom Pharmaceuticals Inc (NAS:PHAT) » Definitions » FCF Yield %

Phathom Pharmaceuticals (Phathom Pharmaceuticals) FCF Yield % : -27.68 (As of May. 15, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Phathom Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Phathom Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-168.39 Mil, and Market Cap is $608.33 Mil. Therefore, Phathom Pharmaceuticals's FCF Yield % for today is -27.68%.

The historical rank and industry rank for Phathom Pharmaceuticals's FCF Yield % or its related term are showing as below:

PHAT' s FCF Yield % Range Over the Past 10 Years
Min: -36.01   Med: -28.66   Max: -22.02
Current: -27.68


During the past 6 years, the highest FCF Yield % of Phathom Pharmaceuticals was -22.02%. The lowest was -36.01%. And the median was -28.66%.

PHAT's FCF Yield % is ranked worse than
66.47% of 1554 companies
in the Biotechnology industry
Industry Median: -14.48 vs PHAT: -27.68

Phathom Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2024 was -3,611.92%.


Phathom Pharmaceuticals FCF Yield % Historical Data

The historical data trend for Phathom Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phathom Pharmaceuticals FCF Yield % Chart

Phathom Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial -8.02 -7.47 -24.79 -31.72 -26.30

Phathom Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -51.28 -10.95 -22.31 -33.46 -44.45

Competitive Comparison of Phathom Pharmaceuticals's FCF Yield %

For the Biotechnology subindustry, Phathom Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phathom Pharmaceuticals's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Phathom Pharmaceuticals's FCF Yield % falls into.



Phathom Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Phathom Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-139.214 / 529.2661
=-26.30%

Phathom Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-69.06 * 4 / 621.525942
=-44.45%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Phathom Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Phathom Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of Phathom Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Phathom Pharmaceuticals (Phathom Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Executives
Molly Henderson officer: CFO and CBO 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Asit Parikh director C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Azmi Nabulsi officer: Chief Operating Officer C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Terrie Curran director C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
David A Socks director, officer: President, CEO, Treas. & Sec. C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Anthony J. Guzzo officer: VP, Chief Accounting Officer C/O US SHIPPING PARTNERS L.P., 399 THORNALL STREET, EDISON NJ 08837
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Todd P. Branning officer: Chief Financial Officer C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Mark Stenhouse director 5505 ENDEAVOR LANE, MADISON WI 53719
Michael F Cola director 435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945
Frazier Life Sciences Ix, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Jonathan S. Edwards director C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Phathom Pharmaceuticals (Phathom Pharmaceuticals) Headlines

From GuruFocus

Phathom Pharmaceuticals Inc CFO and CBO Molly Henderson Sells 2,110 Shares

By GuruFocus Research GuruFocus Editor 05-25-2023